Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975152 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
A Phase 1 study of Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04975152: Active Phase 1 study of Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04975152 is a Phase 1 study of Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 36 participants, below the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04975152, a Phase 1 study of Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
Primary Outcome
Number of participants with adverse events after receiving at least one dose of cemiplimab
Conditions Studied
Interventions
- DRUG Cemiplimab-Rwlc
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What the registry record for NCT04975152 still lists
NCT04975152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab-Rwlc is the first listed.
NCT04975152 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04975152 about?
NCT04975152 is a clinical study titled "Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma". The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
What is the current status of trial NCT04975152?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-10-22. Estimated completion is 2028-03.
What conditions does trial NCT04975152 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04975152?
The interventions under investigation include: Cemiplimab-Rwlc (DRUG).
Who is sponsoring clinical trial NCT04975152?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975152 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04975152's enrollment target sits among peer trials
36 15th of 26 higher than 12 of 26 other Merkel Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Merkel Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of CRD3874-SI in People With Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI